Cite
HARVARD Citation
Schneider, B. et al. (2022). BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of clinical oncology. 40 (4), pp. 345-355. [Online].